Please login to the form below

Nippon Shinyaku

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Nippon Shinyaku's Japan sales performance.

Biosimilar Remicade reaches market in Japan and India

India. In Japan, Nippon Kayaku has launched a biosimilar version of Remicade (infliximab) originally developed by South Korean biotechnology company Celltrion, which was approved for marketing in July. ... Nippon Kayaku said infliximab is the second

Deal Watch table for September 2013

50. 5. Shin Nippon Biomedical / Transcept Pharma. Licence. TO-2070 nasal powder for acute migraine.

First biosimilar mAb gets the nod in EU

In Japan the drug will be co-marketed by Celltrion's development partner Nippon Kayaku. .

New formulations of Pralia and Enbrel head list of new drugs in Japan

line extension - which like its predecessor will be co-promoted by Nippon Boehringer Ingelheim - is expected to provide better control of high blood pressure over 24 hours.

An eye towards the biobetter in South Korea

Location. Status. Herceptin (trastuzumab). CT-P6. Celltrion. Hospira, Nippon Kayaku. Breast cancer. ... Remsima. Celltrion. Hospira, Nippon Kayaku. RA, AS, CD, PA, PS, &UC.

1 2 3 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology